News
Collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Iktos announces deployment of our AI for drug design software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd....
Collaboration with Chiesi Group to use Makya™ for Drug Discovery
Iktos announces deployment of our AI for drug design software Makya™ by Chiesi Group. Follow the link for the full...
Collaboration with UCB in AI for Retrosynthesis
Iktos announced a software licensing agreement related to AI-based retrosynthesis analysis and planning tool Spaya™ ,...
Collaboration with Kadmon
Iktos announces that it has entered into a Research Collaboration Agreement with Kadmon, a clinical-stage...
Collaboration with Facio Therapies
Iktos and Facio Therapies announce collaboration to use AI for FSHD drug design. Follow the link for the full press...
Collaboration With Pfizer in AI for Drug Design
Iktos announces the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer...
Collaboration With Merck KGaA
Iktos announces an additional collaboration agreement in AI for new drug design with Merck KGaA, Darmstadt, Germany, a...
Collaboration with SRI International
Iktos and SRI International announce collaboration to combine Artificial Intelligence and novel automated discovery...
Collaboration with Almirall
Iktos and Almirall announce research collaboration in Artificial Intelligence for new drug design. Follow the link for...
Research Collaboration with Janssen
Iktos announces research collaboration with Janssen to utilise Iktos’s Artificial Intelligence (AI) technology to...
Collaboration with Merck KGa
Iktos announces collaboration with Merck KGaA, Darmstadt, Germany, for use of Iktos AI technology across three drug...
Collaboration with Servier
Iktos and Servier announce the success of their first collaboration, which was designed to evaluate Iktos technology’s...